NEW YORK, July 24 (Praxis Press) Previous reports have documented that sodium cromoglicate has antisickling activity in vitro. Toppet and colleagues studied this antisickling activity in sickle-cell patients given sodium cromoglicate by inhalation or nasal route. Both treatments significantly decreased the percentage of sickle cells in venous blood; this effect was largely retained when the blood was deoxygenated. Sodium cromoglicate may be a clinically useful antisickling drug that has the added benefits of low toxicity and low cost.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Join for free todayAlready a member?Login Here